NREP
NEW REPRESENTATIVE AT IB RECEIVED
29/11/2025
Voltar para busca
Dado oficial do USPTO
CONNECT COLLABORATE ACCELERATE
Sabia que essa marca já está registrada no Estados Unidos?
Antes de investir em nome, identidade e divulgação, valide risco de colisão e estratégia de registro para não perder tempo nem budget.
Active USPTO registrationTipo: VerbalEscritório: US
Snapshot rápido
CONNECT COLLABORATE ACCELERATE
ST13
US500000079273882Classe
42
Pedido
79273882
Registro
6202711
Diagnóstico de risco e oportunidade
Leitura executiva para decisão de naming, protocolo e monitoramento.
Situação USPTO
Active USPTO registration
Tipo de processo
Pedido e registro
Eventos registrados
25
Atualização mais recente
30/11/2025
Classificação
Registrada
Tipo de marca
Verbal
Classes Nice
42
Data de depósito
16/05/2019
Data de registro
24/11/2020
Data de expiração
-
Ação recomendada
Execute uma análise de colidência completa e valide classes antes de qualquer protocolo ou investimento de marca.
Próximo passo
Esses são os detalhes do processo de registro. Mesmo assim, o monitoramento constante é o que garante tranquilidade de que o seu principal ativo continue protegido.
Dados completos do processo
Campos estruturados da autoridade responsável e do histórico oficial.
Data da situação
24/11/2020
Última transação
30/11/2025
Escritório responsável
United States Patent and Trademark Office
Código da situação
700
Cadastro oficial
Principal Register
Código do desenho
4
Tipo de titular
99
Localização do titular
Sheffield, GB
Examinador
MEYERS,MORGAN LAURA
Unidade examinadora
M80
Localização atual
PUBLICATION AND ISSUE SECTION
Titulares e representantes
Titulares
BioPhorum Operations Group Limited
Representantes
Angela P. Doughty Ward and Smith, P.A.
Classificação técnica
Classes Nice
Classe 42
Códigos Vienna
Sem códigos Vienna disponíveis.
Produtos e serviços
Classe 42
Compiling data for research purpose in the field of medical science and medical consultancy; product development consultation; pharmaceutical research and development; consultancy on pharmaceutical product developmentbiopharmaceutical product developmentbiotechnology product developmentmedical device product development; technical research in the field of pharmaceutical studies; technical research in the field of biopharmaceuticalsbiotechnologymedical devices and life science studies; technical consulting in the field of pharmaceutical studies; consultancy in the field of pharmaceutical research; testinginspectionresearchdevelopment of pharmaceutical preparations; research on the subject of pharmaceuticals; providing medical and scientific research information in the field of pharmaceuticals; providing medical and scientific research information in the field of biopharmaceuticalsbiotechnologymedical devices and life sciences; Developing quality control standards for pharmaceuticalbiopharmaceutical and medical device manufacturing; Consultancy services in relation to developing quality control standards for pharmaceuticalbiopharmaceutical and medical device manufacturing; Quality management servicesquality evaluation and analysisquality assurancequality controlin the field of for pharmaceuticalsbiopharmaceuticalsbiotechnologymedical devices; Consultancy services in relation to quality evaluation and analysisquality assurancequality controlin the field of for pharmaceuticalsbiopharmaceuticalsbiotechnologymedical devices; Advisory in the field of quality control of manufactured goods; scientific research in the field of healthcaremedical technologymedical deviceslife sciencespharmaceuticalbiopharmaceuticalbiotechnology; providing consultation in the field of sciencehealthcaremedical technologymedical deviceslife sciencespharmaceuticalbiopharmaceuticalbiotechnology; Promoting collaboration within the scientificresearch and medical communities to achieve advances in the field of healthcarepharmaceuticalsbiopharmaceuticalsmedical devices
Publicações
Histórico de despachos e eventos da marca no USPTO.
25 publicações encontradas
REM3
COURTESY REMINDER - SEC. 71 (6-YR) E-MAILED
24/11/2025
FINO
FINAL DECISION TRANSACTION PROCESSED BY IB
21/03/2021
FICS
FINAL DISPOSITION NOTICE SENT TO IB
27/02/2021
FIMP
FINAL DISPOSITION PROCESSED
27/02/2021
FICR
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
24/02/2021
R.PR
REGISTERED-PRINCIPAL REGISTER
24/11/2020
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
08/09/2020
PUBO
PUBLISHED FOR OPPOSITION
08/09/2020
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
19/08/2020
ALIE
ASSIGNED TO LIE
05/08/2020
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
31/07/2020
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
09/07/2020
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
09/07/2020
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
09/07/2020
RFNT
REFUSAL PROCESSED BY IB
01/02/2020
RFCS
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
11/01/2020
RFRR
REFUSAL PROCESSED BY MPU
11/01/2020
MAFR
APPLICATION FILING RECEIPT MAILED
20/12/2019
RFCR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
18/12/2019
CNRT
NON-FINAL ACTION WRITTEN
17/12/2019
DOCK
ASSIGNED TO EXAMINER
16/12/2019
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
16/12/2019
LIMI
LIMITATION FROM ORIGINAL APPLICATION ENTERED
14/12/2019
REPR
SN ASSIGNED FOR SECT 66A APPL FROM IB
12/12/2019
Proteção contínua da sua marca
Seja avisado a cada novo depósito que ameace CONNECT COLLABORATE ACCELERATE ou a sua marca.
Vigilância profissional por 24 meses: monitoramos o USPTO por você e alertamos a tempo de você se opor — antes que o conflito vire prejuízo.